1. (A) Sequential subtype (B) Branch-off subtype (C) De novo subtype
Supplementary Figure 4
(A) Sequential subtype
(B) Branch-off subtype
(C) De novo subtype
Annotation box
Schema
Intraductal neoplasm with low-grade dysplasia
Flat lesion
Intraductal neoplasm with high-grade dysplasia
Papillary lesion
Invasive cancer
Tubular adenocarcinoma
Mucinous adenocarcinoma
HG IPMN
Underline indicates co-existing IPMN for invasive cancer
Blue circle and
dotted line indicate sampling area
Mutation profile
KRAS G12V (15.3)
Variant allele frequency corrected by neoplastic cellularity of the sample
Mutation variant detected by NGS and/or ddPCR.
Black letter; pathogenic variant other than KRAS or GNAS,
Gray letter; variant unknown significance,
§; variant predicted the functional significance by PROVEAN and/or SIFT.
Immunohistochemical profile (IHC)
(Example)
Strong staining for TP53 and loss of Smad4
TP53
Smad4
p16
β-cat
RNF43 53 S 16 β R
100 80
The red box indicates strong nuclear staining for TP53, strong nuclear and cytoplasmic staining for p16, and nuclear accumulation of β-catenin.
The blue box indicates loss of TP53, Smad4, p16, and RNF43.
The light blue box indicates weak Smad4 staining, suggestive of haploinsufficiency.
The number under box indicates the percentage of tumor cells with abnormal expression.
*, IHC failed due to poor tissue quality or did not determined due to tissue availability.